AstraZeneca is a Swedish-British pharmaceutical and biotechnology company formed in 1999 through the merger of Astra AB and Zeneca Group. Headquartered in Cambridge, UK, with major R&D centers in Gothenburg, Sweden and Gaithersburg, Maryland, the company employs approximately 71,000 people globally. Among the world's largest pharmaceutical companies, AstraZeneca develops treatments for oncology, cardiovascular disease, respiratory conditions, infection, gastrointestinal disease, neuroscience, and inflammation. Publicly listed on the London Stock Exchange and NYSE, the company has built its portfolio through strategic acquisitions including Cambridge Antibody Technology, MedImmune, and Spirogen. In 2016, it relocated its headquarters to Cambridge and refocused on three primary therapeutic areas: Respiratory Inflammation and Autoimmunity, Cardiovascular and Metabolic Disease, and Oncology.
AstraZeneca operates as a large, globally distributed pharmaceutical research and development organization emphasizing scientific excellence and therapeutic innovation. The company maintains a structured corporate environment typical of major pharmaceutical firms, with strategic focus on oncology, cardiovascular and metabolic disease, and respiratory inflammation. The organization recruits globally across scientific, medical, manufacturing, and commercial roles. As a publicly traded company with operations spanning multiple continents, AstraZeneca emphasizes both innovation and operational rigor in its business strategy.
1,072 open now, 1,072 first appeared in the last 30d.